Core Viewpoint - The A-share market has seen a significant pullback in several brain-computer interface (BCI) concept stocks, with notable declines among various companies [1] Group 1: Stock Performance - Companies such as 麦澜德 (Mikland) and 熵基科技 (Entropy Technology) experienced declines exceeding 10% [1] - 诚益通 (Chengyi Tong) and 雷迪克 (Redik) fell over 7% [1] - 博拓生物 (Botuo Bio) and 爱朋医疗 (Aipeng Medical) dropped more than 6% [1] - 可孚医疗 (Kefu Medical) and 翔宇医疗 (Xiangyu Medical) decreased over 5% [1] - 狄耐克 (Dinaike) and 伟思医疗 (Weisi Medical) saw declines greater than 4% [1] Group 2: Company Announcements - Multiple BCI concept stocks issued announcements indicating a cooling off in the market [1] - 航天长峰 (Aerospace Changfeng) stated that the company has not actually engaged in BCI-related business [1] - 伟思医疗 (Weisi Medical) mentioned that new products in the BCI field are still in the early stages of market cultivation [1]

Group 1 - The A-share market has seen a significant pullback in brain-computer interface (BCI) concept stocks, with notable declines in companies such as Mailland and Entropy Technology, which fell over 10% [1] - Several BCI concept stocks have issued announcements indicating a cooling off, with Aerospace Changfeng stating that it has not actually engaged in BCI-related business [1] - Weisi Medical mentioned that its new products in the BCI field are still in the early stages of market cultivation [1] Group 2 - Specific stock performance includes Mailland down 10.68% with a market cap of 5.468 billion, Entropy Technology down 10.13% with a market cap of 10.1 billion, and Chengyi Tong down 7.55% with a market cap of 6.985 billion [2] - Other notable declines include Leedick down 7.14%, Botao Biological down 6.37%, and Aipeng Medical down 6.38% [2] - The overall trend shows that many BCI-related stocks are experiencing a downturn, with declines ranging from 4.33% to 10.68% across various companies [2]

Core Viewpoint - The brain-computer interface (BCI) concept continues to gain traction, with multiple listed companies responding positively to the trend, leading to significant stock price increases in the sector [1]. Company Responses - On January 6, several companies, including Weisi Medical, Sanbo Brain Science, Aipeng Medical, and others, saw their stocks hit the daily limit, with many achieving consecutive gains [3]. - Weisi Medical reported a 20.01% increase in stock price, indicating a strong market response to its developments in the neuro-rehabilitation field, expanding from single-device solutions to comprehensive "diagnosis-treatment-rehabilitation" offerings [4][5]. - Sanbo Brain Science highlighted the promising applications of BCI technology in clinical diagnosis and neuro-rehabilitation, also achieving a 20.01% stock price increase [7]. - Xiangyu Medical announced the establishment of a BCI laboratory and aims to develop a product system covering four major categories, also achieving a two-day stock increase [8]. - Aipeng Medical's stock rose by 20%, emphasizing the role of BCI as a bridge between the brain and external devices [9][10]. - Entropy Technology and Meihua Medical also reported significant stock increases, with the former focusing on BCI and vehicle-road collaboration technologies [11][12]. Industry Developments - Companies are actively engaging in the BCI sector, with Xiangyu Medical entering over 500 medical institutions and aiming for over a thousand top-tier hospitals nationwide, indicating a robust commercialization strategy [15]. - Mcland anticipates obtaining its first BCI medical device registration certificate by Q1 2026, which could accelerate the application of BCI technology in existing product lines [15]. - Chengdu Huayi and Yingjixin are focusing on the foundational hardware for BCI, with Chengdu Huayi developing high-precision ADCs and low-power FPGAs for signal processing [15][16]. - The integration of BCI with embodied intelligence is gaining attention, with companies exploring applications in smart healthcare and rehabilitation [17]. - Blue Si Technology announced its strategic investment in Qiang Brain Technology, which recently secured approximately 2 billion yuan in funding, marking it as the second-largest financing in the BCI field after Neuralink [18]. Market Outlook - The global BCI market is projected to reach approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, driven by technological advancements and increased capital investment [20]. - The transition of BCI from clinical validation to commercial scalability is expected to unlock significant market opportunities in healthcare and consumer sectors [20].

Group 1 - On January 6, a total of 22 stocks appeared on the Longhu list with the presence of Shenzhen Stock Connect special seats among the top five trading departments [1] - The net purchases included stocks such as Shanzi Gaoke, Zhongchao Holdings, and Qiangli New Materials, with net buying amounts of 150.91 million, 104.95 million, and 94.51 million respectively [1][2] - The net sales included stocks like Zhongtian Rocket, Haige Communication, and Tongyu Communication, with net selling amounts of 71.78 million, 54.57 million, and 53.40 million respectively [1][2] Group 2 - The stocks with the highest net purchases included: - Shanzi Gaoke (150.91 million) with a daily increase of 10.12% and a turnover rate of 12.69% [2] - Zhongchao Holdings (104.95 million) with a daily increase of 9.99% and a turnover rate of 34.29% [2] - Qiangli New Materials (94.51 million) with a daily increase of 15.84% and a turnover rate of 36.12% [2] - The stocks with the highest net sales included: - Zhongtian Rocket (-71.78 million) with a daily increase of 8.05% and a turnover rate of 15.76% [2] - Haige Communication (-54.57 million) with a daily increase of 9.98% and a turnover rate of 16.67% [2] - Tongyu Communication (-53.40 million) with a daily increase of 3.38% and a turnover rate of 40.79% [2]

Core Insights - The brain-computer interface (BCI) industry is transitioning from "scientific experiments" to "commercialization," with Neuralink planning large-scale production by 2026, igniting market expectations [1] - China is accelerating its progress in the BCI field through supportive policies and technological breakthroughs, with significant investments being made in the sector [1][12] - The market is characterized as a "0 to 1" incremental market, driven by short-term sentiment from Neuralink's production expectations and favorable domestic policies [1] Investment Landscape - Strong Brain Technology recently completed approximately 2 billion yuan in financing, marking the second-largest funding round in the BCI sector after Neuralink [1] - Investors are advised to focus on companies with core technological advantages, such as self-developed chips and flexible electrodes, as well as those that can achieve commercial closure in rehabilitation and consumer electronics [1] Technology Comparison - The BCI technology landscape is divided into invasive, semi-invasive, and non-invasive routes, each with distinct differences in signal quality, safety, and commercialization timelines [2] - Invasive methods, like those used by Neuralink, involve surgical implantation of electrodes for high-resolution signal acquisition but come with high costs and long development cycles [5] - Non-invasive methods utilize external sensors for signal collection, offering lower costs and safety but facing challenges with signal attenuation [8] Competitive Landscape - The U.S. leads in invasive BCI technology by 2-5 years, while China is catching up, particularly in non-invasive applications where both countries are on par [9][11] - Chinese companies are making significant strides in clinical trials, with several achieving notable milestones in both invasive and non-invasive technologies [12] Company Developments - Companies like BrainCo and Huashan Hospital have completed pioneering clinical trials in invasive BCI systems, demonstrating the ability to control devices through thought [12][13] - Strong Brain Technology has received FDA and CE certifications, positioning itself as a leader in the commercialization of BCI products [12] - Other companies, such as Beijing Chip Intelligence and ZhiDian Medical, are also advancing in the invasive BCI space, with various clinical trials and product developments underway [13][14] Regulatory Environment - The Chinese government has included BCI in its national strategic emerging industries, with plans for independent billing standards and industry regulations to facilitate commercialization [11]

证券代码：300430 证券简称：诚益通 公告编号：2026-001 北京诚益通控制技术集团股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 北京诚益通控制技术集团股份有限公司（以下简称 "公司"）（证券代码： 300430；证券简称：诚益通）股票于 2026 年 1 月 5 日、2026 年 1 月 6 日连续二 个交易日收盘价格涨幅偏离值累计达到 40.30%，根据《深圳证券交易所股票交 易规则》的有关规定，属于股票交易异常波动的情形。 二、公司关注并核实情况说明 三、是否存在应披露而未披露信息的说明 公司董事会确认，除在指定媒体已公开披露的信息外，公司目前没有任何根 据《深圳证券交易所创业板股票上市规则》等有关规定应予以披露而未披露的事 项；董事会也未获悉公司有根据《深圳证券交易所创业板股票上市规则》的有关 规定应予以披露而未披露的、对公司股票及其衍生品种交易价格产生较大影响的 信息；公司前期披露的信息不存在需要更正、补充之处。 4、公司、控股股东和实际控制人不存在关于本公司的应披露 ...

诚益通今日涨停，全天换手率34.79%，成交额24.05亿元，振幅12.94%。龙虎榜数据显示，机构净卖出 1586.71万元，深股通净买入1916.46万元，营业部席位合计净买入4910.61万元。 深交所公开信息显示，当日该股因日收盘价涨幅达20.00%上榜，机构专用席位净卖出1586.71万元，深 股通净买入1916.46万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交4.43亿元，其中，买入成交额为2.48亿 元，卖出成交额为1.95亿元，合计净买入5240.36万元。 具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即买五、卖三、卖五，合计买入金额 4217.66万元，卖出金额5804.37万元，合计净卖出1586.71万元，深股通为第二大买入营业部及第二大卖 出营业部，买入金额为5496.82万元，卖出金额为3580.36万元，合计净买入1916.46万元。 资金流向方面，今日该股主力资金净流入1.89亿元，其中，特大单净流入3.03亿元，大单资金净流出 1.14亿元。近5日主力资金净流入4.45亿元。（数据宝） 诚益通1月6日交易公开信息 | 买/ 卖 | 会员营业部名称 ...

今日涨跌幅居前的概念板块 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002195 | 岩山科 技 | 10.00 | 1.28 | 49272.01 | 80.37 | | 300430 | 诚益通 | 19.99 | 34.79 | 18886.96 | 7.85 | | 301293 | 三博脑 科 | 20.01 | 2.21 | 14128.55 | 46.71 | | 002173 | 创新医 疗 | 10.02 | 1.26 | 11284.03 | 82.52 | | 000516 | 国际医 学 | 9.96 | 2.16 | 9211.37 | 37.34 | | 603716 | 塞力医 疗 | 10.00 | 3.53 | 7079.50 | 38.34 | | 300753 | 爱朋医 | 20.00 | 17.90 | 7057.72 | 11.41 | | --- | --- | --- ...

证券之星消息，1月6日通用设备板块较上一交易日上涨0.87%，诚益通领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。通用设备板块个股涨跌见下表： 从资金流向上来看，当日通用设备板块主力资金净流出21.83亿元，游资资金净流出4789.59万元，散户资 金净流入22.31亿元。通用设备板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002342 | 巨力索具 | 3.15 Z | 13.66% | -1.21亿 | -5.23% | -1.95 Z | -8.43% | | 600783 | 鲁信创投 | 2.00亿 | 10.55% | -1.12 Z | -5.90% | -8812.56万 | -4.65% | | 300430 | 诚益通 | 1.79亿 | 7.44% | -1.66 Z | -6.91% | -1276.06万 ...

1月6日，A股三大指数继续走高，沪指13连阳创十年来新高；截至收盘，沪指涨1.5%报4083点，深证成指涨1.4%，创业板指涨0.75%。 全市场成交额2.83万亿元，较前一交易日增量2650亿元，超4100股上涨，近150股涨停。 | 代码 名称 | 现价 涨跌 | 涨幅 | | --- | --- | --- | | 000001 上证指数 | 4083.67 +60.25 +1.50% | | | 399001 深证成指 14022.55 +193.92 +1.40% | | | | 399006 创业板指 | 3319.29 +24.74 +0.75% | | 盘面上，脑机接口板块继续爆发，三博脑科、伟思医疗及诚益通等十余股涨停；钛白粉企业近日再度集体宣布涨价，钛白粉板块拉 升，安宁股份、钒钛股份涨停；券商股走高，华安证券、华林证券涨停；工业金属、硅能源、电子纸及化学原料等板块涨幅居前。另 外，CPO概念、美容护理、F5G概念、噪声防治等板块跌幅居前。 具体来看： 脑机接口板块全天强势，倍益康30cm涨停，伟思医疗、三博脑科、爱朋医疗、翔宇医疗等20cm涨停。 消息面上，市场交易活跃度维持高位，上证指 ...